The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer.
Tiffany A. Traina
Consultant or Advisory Role - Eisai; Genentech; Prostrakan
Honoraria - Celgene; Eisai; Genentech; Merck; Prostrakan
Research Funding - AstraZeneca; Eisai; Genentech; Janssen; Medivation; Novartis; ZIOPHARM Oncology
Joyce O'Shaughnessy
Consultant or Advisory Role - Medivation
Catherine Margaret Kelly
No relevant relationships to disclose
Lee Steven Schwartzberg
No relevant relationships to disclose
Ayca Gucalp
No relevant relationships to disclose
Amy C. Peterson
Employment or Leadership Position - Medivation
Consultant or Advisory Role - Medivation
Iulia Cristina Tudor
Employment or Leadership Position - Medivation
Stock Ownership - Medivation
Martha Elizabeth Blaney
Employment or Leadership Position - Medivation
Consultant or Advisory Role - Medivation
Joyce Leta Steinberg
Employment or Leadership Position - Astellas Pharma
Maureen E. Trudeau
Consultant or Advisory Role - Astellas Pharma (U)
Clifford A. Hudis
No relevant relationships to disclose
Peter Schmid
No relevant relationships to disclose